Antibody-drug conjugate · Kills target cells, directed at CD46 (membrane cofactor protein) (CD46) · developed by Kyntra Bio
FOR46 is an antibody-drug conjugate built from a human monoclonal antibody that binds a conformational epitope on CD46, an immune modulatory receptor expressed on certain tumor cells. After binding and internalization, its cytotoxic payload kills the CD46-expressing cells. It is being studied in metastatic castration-resistant prostate cancer and prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06842498 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Recruiting | KYNB |
| NCT05011188 | Phase 1/2 | Metastatic Castration-resistant Prostate Cancer | Active not recruiting | KYNB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Castration-resistant Prostate CancerProstate Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.
See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYNB catalysts and pipeline →